

For Immediate Release

Company Name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code Number: 4568, First Section, Tokyo, Osaka, Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com/>

Announcement regarding ActHib[®]
(pediatric vaccine for the prevention of infections caused by *Haemophilus influenza Type b*)
launch

Tokyo, December 19, 2008- DAIICHI SANKYO COMPANY, LIMITED announces that ActHIB[®] which prevents the infectious diseases caused by *Haemophilus Influenza Type b* (License holder: Sanofi Pasteur Daiichi-Sankyo Vaccine Co., Ltd., Manufacturer: sanofi pasteur S.A (France), Distributor: DAIICHI SANKYO COMPANY, LIMITED) has been launched today.

Haemophilus influenzae type b (Hib) enters the body through the nose or throat by cough, sneeze and can spread to cause meningitis (an infection of the coverings of the brain and spinal cord), sepsis, infection of the epiglottis, and other serious infections. ActHIB[®] have been already used over more than 100 countries worldwide for prevention of those diseases caused by *Haemophilus Influenzae type b* (Hib).